Emerging Treatments and the Clinical Trial Landscape for Hidradenitis Suppurativa Part I: Topical and Systemic Medical Therapies

• Published in: Dermatology and therapy Vol. 13; no. 8; pp. 1661 - 1697
• Main Authors: Fragoso, Natalie M., Masson, Rahul, Gillenwater, T. Justin, Shi, Vivian Y., Hsiao, Jennifer L.
• Format: Journal Article
• Language: English
• Published: Cheshire Springer Healthcare 01.08.2023; Springer; Adis, Springer Healthcare
• Subjects: Adalimumab; Clinical trials; Dermatologic agents; Dermatology; Drug therapy; Forecasts and trends; Formulae, receipts, prescriptions; Health aspects; Hidradenitis suppurativa; Homeopathy; Innovations; Internal Medicine; Materia medica and therapeutics; Medical centers; Medical colleges; Medicine; Medicine & Public Health; Methicillin; Oral and Maxillofacial Surgery; Oral medication; Plastic Surgery; Quality of Life Research; Review; Skin diseases; Surgery, Plastic; Systemic; Therapeutics; Topical; Topical medication; Treatment; United States; Clinical trials; Systemic; Topical; Treatment; Hidradenitis suppurativa
• ISSN: 2193-8210; 2190-9172
• DOI: 10.1007/s13555-023-00956-6

Hidradenitis suppurativa (HS) is an oftentimes debilitating condition that presents with painful nodules, abscesses, and sinus tracts. This condition is challenging to treat, in part because the pathogenesis of the condition is incompletely understood but also because there are limited therapeutic options. HS research is undergoing explosive growth with multiple new molecular pathways under study, which will hopefully lead to improved disease control for patients. Part I of this review will provide an overview of the emerging topical and systemic therapies under investigation for HS.